2024 CTAD Presentation

/in , , , , , , /by

2024 CTAD Presentation:

ALTITUDE-AD: Use of a Validated p-tau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Participants with Early Alzheimer’s Disease

Download
File Type: pdf
File Size: 2 MB
Categories: 2024
Tags: 2024, ALTITUDE-AD, CTAD, Presentation, pTau217, sabirnetug, TwentyTwentyFour